Novartis: MS drug beneficial for children and teenagers
(CercleFinance.com) - Results from a Phase III study published in the New England Journal of Medicine (NEJM) show that Novartis' orally administered drug Gilenya was significantly beneficial for children and teenagers who suffer from multiple sclerosis, the Swiss biopharmaceutical group said on Thursday.
The late-stage study met the primary endpoint of significantly reducing the rate of relapses when compared to intramuscular injections over a period of up to two years.
The study also met several secondary clinical and imaging endpoints, Novartis said.
Children and teenagers with multiple sclerosis experience more frequent and often more severe relapses than those seen in adults.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The late-stage study met the primary endpoint of significantly reducing the rate of relapses when compared to intramuscular injections over a period of up to two years.
The study also met several secondary clinical and imaging endpoints, Novartis said.
Children and teenagers with multiple sclerosis experience more frequent and often more severe relapses than those seen in adults.
Copyright (c) 2018 CercleFinance.com. All rights reserved.